Evaluation of antihemorrhagic activity of V. F.
In the prophylaxis of surgical interventions performed in the Dental Clinic for dental avulsions under general anesthesia, the V. F. (peptides deriving from the enzymatic degradation of bovine Factor VIII) has been shown to be particularly active in the reduction of the quantity of blood lost per tooth, corresponding to a reduction in blood loss of an average of 40% to 45%. The "double blind" experiment confirmed a significant hemostatic capacity of the preparation. V. F. in extremely small doses (1 mg/day) divided into two daily, oral administrations, isn't toxic, isn't habit forming and doesn't provoke immunological reactions. On the basis of its positive characteristics (diminution of blood lost without alteration of the parameters of coagulation or platelet aggregation), V. F. seems to be the preparation of choice for the treatment of hemorrhagic diathesis not accompanied by coagulation defect, and also as a preventive measure in minor surgical interventions where small vessels are involved and hemostasis cannot be achieved surgically.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005169:Factor VIII / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D006472:Oral Hemorrhage / Q000188:drug therapy* / Q000517:prevention & control; D010455:Peptides / Q000627:therapeutic use*; D014081:Tooth Extraction
D010455:Peptides; D005169:Factor VIII